Dopamine is a neurotransmitter commonly recognized as a molecule having physiological roles that include cognition, learning, reward and other behavior and physical functions. There are 5 different receptor subtypes, DRD1 to DRD5, which are further divided into 2 groups, D1-like receptors (which include DRD1 and DRD5), and D2-like receptors (DRD2-DRD4). The 2 groups are G-protein coupled receptors and are all activated by dopamine, but have different signaling pathways: D1-like receptors are coupled with GNAS/Gsa, which activate adenylate cyclase (ADCY) that leads to the increase of cyclic adenosine monophosphate (cAMP) whereas D2-like receptors are coupled with GNAI/Gia, which inhibit ADCY activity and cAMP production. Through the five G-protein-coupled receptors, DRD1-DRD5, Dopamine modulates reward and motor control along with immune responses and the regulation of inflammation. Findings indicate that DRD5 has a 10-fold higher affinity for dopamine than DRD1.
Anti-DRD5-SAP is a bonded toxin between a biotinylated antibody to dopamine receptor D5 and the secondary conjugate Streptavidin-ZAP containing the ribosome-inactivating protein, saporin.
Anti-DRD5-SAP eliminates cells expressing human, mouse, rat dopamine receptor D5. All other cells are left untouched.
The following control is included for validating the specificity of the beta conjugate: BIgG-SAP Rat (Cat. #IT-73)
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.
keywords: dopamine, DRD5, D5, anti-dopamine receptor, anti-DRD5, targeted conjugate, streptavidin, saporin